Cipla Limited (NSE:CIPLA)
1,310.90
-6.30 (-0.48%)
Apr 28, 2026, 3:29 PM IST
Cipla Revenue
Cipla had revenue of 69.63B INR in the quarter ending December 31, 2025, with 0.02% growth. This brings the company's revenue in the last twelve months to 279.67B, up 4.67% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.67B
Revenue Growth
+4.67%
P/S Ratio
3.77
Revenue / Employee
9.23M
Employees
30,313
Market Cap
1,055.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mankind Pharma | 139.14B |
| Zydus Lifesciences | 260.89B |
| Aurobindo Pharma | 331.82B |
| Glenmark Pharmaceuticals | 165.10B |
| Divi's Laboratories | 103.14B |
| Alkem Laboratories | 142.53B |
| Laurus Labs | 67.22B |
| Ipca Laboratories | 95.06B |
Cipla News
- 1 day ago - Cohance Lifesciences Hits 20% Upper Circuit After Appointing Former Cipla CEO Umang Vohra as Chairman and Group CEO - Business Upturn
- 4 days ago - Cipla faces $100 million revenue risk as USFDA alert delays restart beyond FY27, says Macquarie - Business Upturn
- 4 days ago - Cipla Shares Fall 3% as Partner Unit Gets FDA Import Alert, Lanreotide Revenue at Risk - Business Upturn
- 4 days ago - Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup - Business Upturn
- 5 days ago - Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more - Business Upturn
- 5 days ago - Cipla gets USFDA nod for first AB-rated generic of Ventolin HFA - Business Upturn
- 5 days ago - Cipla receives USFDA approval for first AB-rated generic of Ventolin HFA - Business Upturn
- 6 days ago - Pharma sector stocks today, April 22: Natco Pharma up 1.4%, Lupin falls 1.01%, Cipla down 0.73% - Business Upturn